PharmacoLearn

MRA103T Clinical Research Regulations, M.Pharm Semester 1

Unit 4: Clinical Research Related Guidelines

Free notes at pharmacolearn.fyi

4.1 Guidelines: the layer between law and practice

Unit 3 stated the laws; this unit teaches the instruments that tell professionals how the laws are satisfied. A **guideline** is not legislation, and the distinction matters in examinations and in practice: a rule binds, a guideline states the authority's current thinking or the profession's agreed standard, and departing from it is possible where the departure is justified, while departing from a rule is a violation. Yet the guidelines of this unit are the documents a regulatory affairs professional actually works from daily, because ICH GCP governs every protocol decision, ICMR's guidelines govern every Indian ethics file, and the ICH efficacy series answers the design questions that recur in every programme. The unit reads them in the syllabus's order: the GCP family first, then the device guidance, then the five efficacy guidelines, and it closes with the biostatistics principles that all of them presuppose.

4.2 ICH GCP E6: the working content

Unit 2 gave E6 its origin; here is what it contains. The guideline states thirteen **principles of GCP**, whose heads every student should be able to reproduce in substance: trials are conducted in accordance with the Declaration of Helsinki; foreseeable risks are weighed against anticipated benefits; the rights, safety and well being of participants prevail over science and society; the available information on the product must support the trial; the trial is described in a clear, detailed protocol; the protocol receives prior ethics committee approval; medical decisions rest with qualified physicians; everyone involved is qualified by education, training and experience; informed consent is freely given and documented; trial information is recorded, handled and stored so that it can be accurately reported, interpreted and verified; confidentiality of records is protected; the product is manufactured and handled under GMP; and systems with procedures assuring quality are implemented in every aspect. The balance of the guideline distributes the operational duties the principles imply: the ethics committee's composition and procedures (Unit 2), the **investigator's** responsibilities (protocol compliance, consent, records, safety reports), the **sponsor's** responsibilities (quality management, monitoring, auditing, data handling, safety information and its expedited reporting, trial master file discipline), and the **essential documents** that permit evaluation of the trial's conduct.

4.3 Indian GCP guidelines

India's own **Good Clinical Practice Guidelines**, issued by CDSCO under the Drugs and Cosmetics framework in 2001, adapt the same architecture to Indian conditions and remain the syllabus's named national counterpart to E6. Their emphases are the Indian specifics the international text cannot carry: ethics committees in Indian institutions, informed consent in the languages and literacy conditions of Indian participants, and the documentation the Indian regulator expects. The regulatory writer reads the Indian GCP with the NDCT Rules, not instead of them: where the Rules of 2019 now prescribe directly (ethics committee registration, compensation, reporting), the Rules prevail. This layering, statute, rules, national guideline, international guideline, recurs across the branch.

4.4 ICMR ethical guidelines for biomedical research

The **Indian Council of Medical Research** is the apex body for biomedical research in India, and its **National Ethical Guidelines for Biomedical and Health Research Involving Human Participants** (the

current edition is the 2017 revision, successor to the ethical guidelines of 2000 and 2006 that the syllabus era text cites) are the ethics constitution for research that is not a drug trial: academic studies, epidemiology, public health research, research on stored samples and data, and the human research of every institution whether or not a licence is involved. Their content runs wider than GCP: general principles drawn from the same Belmont and Helsinki root; responsible conduct of research; ethical review procedures, including the registration of ethics committees for biomedical and health research with the designated authority in the Department of Health Research (the counterpart, for non trial research, of the CLA registration of Unit 2); informed consent including waiver conditions and community consent; vulnerability; biological materials and data governance; and the special fields, from genetic research to stem cell research (with the ICMR DBT stem cell guidelines that MRA104T meets again). A sponsor trial answers to NDCT and GCP; an investigator initiated study answers to ICMR; most institutions answer to both, and their ethics committees sit at the junction, which is why this subject teaches both codes.

4.5 CDSCO guidelines

The **Central Drugs Standard Control Organization**, headed by the Drugs Controller General (India), is the Central Licensing Authority of Units 2 and 3, and its published guidelines and guidance documents are the fourth layer of the Indian system: practical instructions on applications, dossiers, checklists and formats through which CDSCO tells applicants how it expects the Rules to be complied with, including guidance on clinical trial applications, bioavailability and bioequivalence studies and serious adverse event reporting. The skill this item teaches is hierarchical reading: an applicant follows the Act, then the Rules made under it, then CDSCO's guidance on the Rules, and treats a conflict between layers as a question to resolve upward, never as a freedom to choose.

4.6 GHTF Study Group 5: clinical evidence for devices

Devices take their guidance from a different family. The Global Harmonization Task Force, the pre 2012 harmonisation body for devices (succeeded by the International Medical Device Regulators Forum, IMDRF, whose guidance documents carry the work forward), organised its output in study groups, and **Study Group 5** owned clinical evidence. Its guidance documents give the device world the definitions Unit 1 closed with: what counts as clinical data, how **clinical evaluation** is performed and reported across a device's life, and when and how a **clinical investigation** must be designed and conducted to fill the gaps evaluation finds. SG5's product is the device counterpart of this unit's drug guidelines, and its descendant documents, read with ISO 14155 (Unit 5), are the standards against which notified bodies and regulators judge device clinical evidence in Europe and in the Indian device framework alike.

4.7 ICH E4: dose response information

The five ICH efficacy guidelines the syllabus names are design instruments, and **E4, Dose Response Information to Support Drug Registration** (1994), is the one that governs the numbers on the label's first page. Its doctrine: dose response should be studied deliberately, not stumbled into; the dose ranging of Phase II (Unit 1) should characterise the dose response curves for both benefit and harm in the population, identify the starting dose, the ceiling beyond which benefit flattens or risk climbs, and the titration rules for individuals; and exposure response (concentration against effect) analysis may supplement dose response where pharmacokinetics vary. E4 is the guideline behind every assessor's question of the form: why this dose, in this population, on this schedule, and its absence is visible in applications whose doses appear chosen by habit.

4.8 ICH E7: studies in the geriatric population

E7, Studies in Support of Special Populations: Geriatrics, answers the special populations doctrine of Unit 2 for the group that consumes the most medicines. Its position: the elderly are to be included in drug development in meaningful numbers rather than protected by exclusion, because exclusion exports uncertainty into practice; geriatric evaluation should reflect the age distribution of the disease, attend to the very old, and examine the effects of age related renal and hepatic decline, of comorbidity and of the polypharmacy that defines real geriatric prescribing; and where a drug will mainly be used in the elderly, the database should be built accordingly. E7 is brief and its logic exemplary, which is why the syllabus pairs it with the population guidelines around it: the question is never whether a group is difficult to study, but what evidence the group is owed.

4.9 ICH E8: general considerations for clinical trials

E8, General Considerations for Clinical Trials, is the framework document of the efficacy series, the one that states the principles the others particularise: the development programme viewed whole, from exploratory to confirmatory; objectives stated before design; the taxonomy of study designs (Unit 1's vocabulary, harmonised); endpoints and their validity; bias and its controls, randomisation, blinding and the analysis choices that protect them; and the ethical and quality frame within which all of it sits. A revision, E8(R1), has modernised the text around critical to quality factors: the design features whose failure would invalidate the study should be identified prospectively and built into the protocol. E8 is the first of the five to read and the answer key to the others.

4.10 ICH E10: choice of control group

E10, Choice of Control Group and Related Issues in Clinical Trials, operationalises section 2.9. It classifies the controls (placebo, no treatment, dose response, active control, external or historical control, and combinations), states what inference each can support, and works through the two hard problems: the **ethics** of placebo and no treatment control, resolved by the harm graded position Unit 2 described; and the logic of **active control non inferiority trials**, whose conclusion depends on assay sensitivity, on the assumption that the control would have beaten placebo in this trial as it did in its own, an assumption the design must make defensible rather than merely assert. E10 is why control choice appears in every serious protocol review: the control is the instrument of inference, and a trial whose control cannot answer the question is a trial whose participants were exposed for nothing.

4.11 ICH E11: clinical investigation in the paediatric population

E11, Clinical Investigation of Medicinal Products in the Paediatric Population, with its later addendum on extrapolation, applies the special populations doctrine to children. Its structure: development in children should be considered early and planned, not appended after adult approval; studies proceed with age appropriate formulations, endpoints and consent arrangements (parental permission and the child's assent, section 2.10); age categories and the staged approach, usually from older to younger children, order the programme; pharmacokinetic study often carries more weight than in adults, because efficacy can sometimes be extrapolated from adult data where disease and response are sufficiently similar, the framework the addendum formalised; and long term safety follow up, growth and development included, outlasts the trial itself. E11 closes the syllabus's five with the population in whom the consent doctrine is most layered.

© 2026 PharmacoLearn | pharmacolearn.fyi



Figure: The five ICH efficacy guidelines of Unit 4 and the design question each one answers (Unit 4, sections 4.7 to 4.11).

4.12 General biostatistics principles applied in clinical research

The unit's last item names the discipline that makes trials evidentiary. The general principles, stated at the level this subject requires: **Randomisation** allocates by chance to remove selection bias, and **blinding** keeps participants, investigators and assessors from steering the result. **Endpoints** are defined before the trial: the primary endpoint carries the claim, secondary endpoints support it, and surrogate endpoints must be justified as predicting clinical benefit. **Sample size** is computed from the effect worth detecting, the variance, and the accepted error rates, and an underpowered trial is an ethical defect as well as a statistical one, because it spends participants without buying knowledge. **Hypotheses and significance**: a prespecified analysis plan fixes the test, the significance level and the handling of multiplicity before the data are seen. **Analysis populations** are declared in advance: the intention to treat set, all randomised participants analysed as randomised, preserving the protection randomisation bought; and the per protocol set, used in support, never as a quiet substitute. **Interim analysis** is permitted only under the discipline of the DSMB and the statistical penalty for looking. These principles are the criteria by which assessors read Module 5 of the dossier of MRA102T, and by which the FDA and EMA guidance of the next unit judges the data placed before it.

More free M.Pharm notes and unit wise PDFs at pharmacolearn.fyi
Free video lectures on the PharmacoLearn YouTube channel